A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy. - Nardi V; Schwieterman J; Ansari S; Kincaid Z; Azhar M; Yousuf T; Amir N; Khan A; Kesarwani M; Ryall S; Brunner AM; Capilla Guerra MR; et al. (MedRxiv : the preprint server for health sciences, 2026)